AMAG Pharmaceuticals Announces Leadership Changes
11 Juni 2020 - 1:00PM
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that
Edward (Ted) Myles, Chief Financial and Chief Operating Officer, is
leaving the Company. Brian Piekos, Senior Vice President of
Finance, has been appointed interim Chief Financial Officer and
will become a member of the company’s Executive Leadership Team.
Anthony (Tony) Casciano has been appointed Chief Operating Officer
and will add significant operational responsibilities to his role
in addition to leading commercial operations. Both appointments are
effective immediately.
“Our key priorities are to grow our core business, advance our
pipeline and unlock shareholder value,” said Scott Myers, AMAG’s
Chief Executive Officer. “AMAG’s succession planning process
ensures new leaders can contribute to advance the company. I’m
excited to have Brian’s experience, capabilities and deep financial
acumen brought to the Executive Team, and the Board of Directors
and I have full confidence in his leadership. Broadening Tony’s
role to include additional responsibilities will have a positive
impact on AMAG’s business and I look forward to partnering with him
on refining our business practices and unlocking value. We
appreciate the succession plan Ted has put into place and wish him
well in his future endeavors.”
Mr. Piekos joined AMAG in 2015 and has held a number of senior
management positions with the Company. In his most recent role as
Senior Vice President of Finance, Mr. Piekos has provided oversight
of AMAG’s financial planning and reporting, tax, treasury and
strategic sourcing processes. He has more than 20 years of
corporate finance experience including strategic planning,
financial reporting and capital market activities. Prior to AMAG,
he held positions of increasing responsibility at Cubist
Pharmaceuticals. Mr. Piekos began his career in investment banking
having served as Vice President at Leerink Partners and as an
analyst at Needham & Company.
Mr. Casciano brings more than 20 years of commercial experience
within the pharmaceutical industry. He joined AMAG in September
2016 and has since held positions of increasing responsibility with
the Company. In his role as Chief Operating Officer, he will
continue overseeing commercial activities, as well as technical
operations, global supply chain and information technology for the
Company. Prior to AMAG, Mr. Casciano spent 16 years career at
Sanofi, where he held multiple commercial leadership roles across a
range of departments and therapeutic areas.
ABOUT AMAG AMAG is a pharmaceutical company
focused on bringing innovative products to patients with unmet
medical needs. The company does this by leveraging its development
and commercial expertise to invest in and grow its pharmaceutical
products across a range of therapeutic areas. For additional
company information, please visit www.amagpharma.com.
Forward Looking StatementsThis press release
contains forward-looking information about AMAG within the meaning
of the Private Securities Litigation Reform Act of 1995 and other
federal securities laws. Any statements contained herein which do
not describe historical facts, including, among others, statements
regarding expectations with respect to the leadership changes and
the impact on AMAG’s business, are forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking
statements.
Such risks and uncertainties include, among others, risks and
uncertainties related to recent leadership changes, including
potential disruption to the business and to management caused by
leadership changes and succession efforts, and the potential impact
on AMAG’s ability to retain and hire talents, as well as those
risks identified in AMAG’s filings with the U.S. Securities and
Exchange Commission (SEC), including its Annual Report on Form 10-K
for the year ended December 31, 2019, its Current Reports on Form
8-K, its Quarterly Reports on Form 10-Q, including for the quarter
ended March 31, 2020, and in any subsequent filings with the SEC,
which are available at the SEC’s website at www.sec.gov. Any such
risks and uncertainties could materially and adversely affect
AMAG’s results of operations, its profitability and its cash flows,
which would, in turn, have a significant and adverse impact on
AMAG’s stock price. AMAG cautions you not to place undue reliance
on any forward-looking statements, which speak only as of the date
they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward‐looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc.
AMAG CONTACTSInvestors & Media:Rushmie
Nofsinger(781) 530-6838
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Mai 2023 bis Mai 2024